|
|
帕博利珠单抗在三阴性乳腺癌中的应用
|
Abstract:
乳腺癌是全球最常见的癌症，而三阴性乳腺癌(TNBC)是乳腺癌中恶性程度最高的亚型，标准的治疗手段仅限于手术、化疗和放疗，但是治疗效果并不理想。TNBC具有高度异质性以及较强的免疫原性，因此，免疫疗法以及靶向治疗被证明可以提高TNBC的总体生存率和反应，为TNBC提供了有前景的治疗选择。在这篇综述中，我们总结了在TNBC患者中基于免疫检查点抑制剂(ICIs)的各种治疗策略的研究进展，并探讨TNBC免疫治疗前景。
Breast cancer is the most common cancer in the world, and triple-negative breast cancer is the most malignant subtype of breast cancer. The standard treatment methods are limited to surgery, chemotherapy and radiotherapy, but the treatment effect is not ideal. Triple-negative breast cancer has high heterogeneity and strong immunogenicity. Therefore, immunotherapy and targeted ther-apy have been proved to improve the overall survival rate and response of triple-negative breast cancer, providing a promising treatment option for triple-negative breast cancer. In this review, we summarized the research progress of various treatment strategies based on immune checkpoint inhibitors in triple-negative breast cancer patients, and discussed the prospect of triple-negative breast cancer immunotherapy.
| [1] | Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660 |
| [2] | Xia, C., Dong, X., Li, H., et al. (2022) Cancer Statistics in China and United States, 2022: Profiles, Trends, and Determinants. Chinese Medical Journal (England), 135, 584-590. https://doi.org/10.1097/CM9.0000000000002108 |
| [3] | Li, Y., Zhang, H., Merkher, Y., et al. (2022) Recent Ad-vances in Therapeutic Strategies for Triple-Negative Breast Cancer. Journal of Hematology & Oncology, 15, Article No. 121. https://doi.org/10.1186/s13045-022-01341-0 |
| [4] | Borri, F. and Granaglia, A. (2021) Pathology of Triple Negative Breast Cancer. Seminars in Cancer Biology, 72, 136-145. https://doi.org/10.1016/j.semcancer.2020.06.005 |
| [5] | Liedtke, C., Mazouni, C., Hess, K.R., et al. (2023) Response to Neoadjuvant Therapy and Long-Term Survival in Patients with Triple-Negative Breast Cancer. Journal of Clinical Oncology, 41, 1809-1815.
https://doi.org/10.1200/JCO.22.02572 |
| [6] | Kumar, A.R., Devan, A.R., Nair, B., et al. (2021) Harnessing the Im-mune System against Cancer: Current Immunotherapy Approaches and Therapeutic Targets. Molecular Biology Reports, 48, 8075-8095.
https://doi.org/10.1007/s11033-021-06752-9 |
| [7] | Jiang, Y.Z., Ma, D., Suo, C., et al. (2019) Genomic and Tran-scriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell, 35, 428-440.e5. |
| [8] | Liu, Z., Li, M., Jiang, Z., et al. (2018) A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer. Translational Oncology, 11, 311-329. https://doi.org/10.1016/j.tranon.2018.01.011 |
| [9] | Barrett, M.T., Lenkiewicz, E., Malasi, S., et al. (2018) The Association of Genomic Lesions and PD-1/PD-L1 Expression in Re-sected Triple-Negative Breast Cancers. Breast Cancer Research, 20, Article No. 71.
https://doi.org/10.1186/s13058-018-1004-0 |
| [10] | Hom？ek, A., Radosavljevi？, D., Mileti？, N., et al. (2022) Review of the Clinical Pharmacokinetics, Efficacy and Safety of Pembrolizumab. Current Drug Metabolism, 23, 460-472. https://doi.org/10.2174/1389200223666220609125013 |
| [11] | Nanda, R., Chow, L.Q.M., Dees, E.C., et al. (2016) Pembrolizumab in Patients with Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. Journal of Clinical Oncology, 34, 2460-2467.
https://doi.org/10.1200/JCO.2015.64.8931 |
| [12] | Adams, S., Schmid, P., Rugo, H.S., et al. (2019) Pembrolizumab Monotherapy for Previously Treated Metastatic Triple-Negative Breast Cancer: Cohort A of the Phase II KEYNOTE-086 Study. Annals of Oncology, 30, 397-404.
https://doi.org/10.1093/annonc/mdy517 |
| [13] | Adams, S., Loi, S., Toppmeyer, D., et al. (2019) Pembrolizumab Monotherapy for Previously Untreated, PD-L1-Positive, Metastatic Triple-Negative Breast Cancer: Cohort B of the Phase II KEYNOTE-086 Study. Annals of Oncology, 30, 405-411. https://doi.org/10.1093/annonc/mdy518 |
| [14] | Winer, E.P., Lipatov, O., Im, S.A., et al. (2021) Pembrolizumab ver-sus Investigator-Choice Chemotherapy for Metastatic Triple-Negative Breast Cancer (KEYNOTE-119): A Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 22, 499-511. https://doi.org/10.1016/S1470-2045(20)30754-3 |
| [15] | Li, Z., Lai, X., Fu, S., et al. (2022) Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency. Advanced Science (Weinh), 9, Article ID: 2201734.
https://doi.org/10.1002/advs.202201734 |
| [16] | Vranic, S., Cyprian, F.S., Gatalica, Z., et al. (2021) PD-L1 Status in Breast Cancer: Current View and Perspectives. Seminars in Cancer Biology, 72, 146-154. https://doi.org/10.1016/j.semcancer.2019.12.003 |
| [17] | De Almeida Gon？alves, V.D.M., De Almeida Camargo Filho, M.F., Zaleski, T., et al. (2021) Chemotherapy in Focus: A Meta-Analysis Confronts Immunotherapy in the Treatment of Advanced Melanoma. Critical Reviews in Oncology/Hematology, 161, Article ID: 103304. https://doi.org/10.1016/j.critrevonc.2021.103304 |
| [18] | Du, C., Chen, Y., Zhou, Y., et al. (2023) Neo-Adjuvant Chemotherapy plus Immunotherapy in Resectable N1/N2 NSCLC. BMC Cancer, 23, Article No. 1260. https://doi.org/10.1186/s12885-023-11745-x |
| [19] | Lu, J., Liu, X., Liao, Y.P., et al. (2017) Nano-Enabled Pancreas Cancer Immunotherapy Using Immunogenic Cell Death and Reversing Immunosuppression. Nature Communications, 8, Article No. 1811.
https://doi.org/10.1038/s41467-017-01651-9 |
| [20] | Zhang, W., Zhang, K., Liu, C., et al. (2023) Hepatic Arterial In-fusion Chemotherapy Combined with Anti-PD-1/PD-L1 Immunotherapy and Molecularly Targeted Agents for Advanced Hepatocellular Carcinoma: A Real World Study. Frontiers in Immunology, 14, Article ID: 1127349. https://doi.org/10.3389/fimmu.2023.1127349 |
| [21] | Tolaney, S.M., Kalinsky, K., Kaklamani, V.G., et al. (2021) Eribulin plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study. Clinical Cancer Research, 27, 3061-3068.
https://doi.org/10.1158/1078-0432.CCR-20-4726 |
| [22] | Cortes, J., Cescon, D.W., Rugo, H.S., et al. (2020) Pem-brolizumab plus Chemotherapy versus Placebo plus Chemotherapy for Previously Untreated Locally Recurrent Inopera-ble or Metastatic Triple-Negative Breast Cancer (KEYNOTE-355): A Randomised, Placebo-Controlled, Double-Blind, Phase 3 Clinical Trial. The Lancet, 396, 1817-1828.
https://doi.org/10.1016/S0140-6736(20)32531-9 |
| [23] | Cortes, J., Rugo, H.S., Cescon, D.W., et al. (2022) Pem-brolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. The New England Journal of Medicine, 387, 217-226. https://doi.org/10.1056/NEJMoa2202809 |
| [24] | Huang, M., O’Shaughnessy, J., Haiderali, A., et al. (2022) Q-TWiST Analysis of Pembrolizumab Combined with Chemotherapy as First-Line Treatment of Metastatic Tri-ple-Negative Breast Cancer That Expresses PD-L1. European Journal of Cancer, 177, 45-52. https://doi.org/10.1016/j.ejca.2022.09.029 |
| [25] | Schmid, P., Salgado, R., Park, Y.H., et al. (2020) Pembrolizumab plus Chemotherapy as Neoadjuvant Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: Results from the Phase 1b Open-Label, Multicohort KEYNOTE-173 Study. Annals of Oncology, 31, 569-581. https://doi.org/10.1016/j.annonc.2020.01.072 |
| [26] | Nanda, R., Liu, M.C., Yau, C., et al. (2020) Effect of Pembroli-zumab plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women with Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncology, 6, 676-684. https://doi.org/10.1001/jamaoncol.2019.6650 |
| [27] | Schmid, P., Cortes, J., Pusztai, L., et al. (2020) Pembrolizumab for Early Triple-Negative Breast Cancer. The New England Journal of Medicine, 382, 810-821. https://doi.org/10.1056/NEJMoa1910549 |
| [28] | Schmid, P., Cortes, J., Dent, R., et al. (2022) Event-Free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. The New England Journal of Medicine, 386, 556-567. https://doi.org/10.1056/NEJMoa2112651 |
| [29] | Schmid, P., Cortés, J., Dent, R.A., et al. (2023) LBA18 Pembroli-zumab or Placebo plus Chemotherapy Followed by Pembrolizumab or Placebo for Early-Stage TNBC: Updated EFS Results from the Phase III KEYNOTE-522 Study. Annals of Oncology, 34, S1257. https://doi.org/10.1016/j.annonc.2023.10.008 |
| [30] | Shen, J., Zhao, W., Ju, Z., et al. (2019) PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Inde-pendent of BRCAness. Cancer Research, 79, 311-319.
https://doi.org/10.1158/0008-5472.CAN-18-1003 |
| [31] | Jiao, S., Xia, W., Yamaguchi, H., et al. (2017) PARP In-hibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clinical Cancer Research, 23, 3711-3720.
https://doi.org/10.1158/1078-0432.CCR-16-3215 |
| [32] | Vinayak, S., Tolaney, S.M., Schwartzberg, L., et al. (2019) Open-Label Clinical Trial of Niraparib Combined with Pembrolizumab for Treatment of Advanced or Metastatic Tri-ple-Negative Breast Cancer. JAMA Oncology, 5, 1132-1140. https://doi.org/10.1001/jamaoncol.2019.1029 |
| [33] | Khadela, A., Chavda, V.P., Soni, S., et al. (2022) An-ti-Androgenic Therapies Targeting the Luminal Androgen Receptor of a Typical Triple-Negative Breast Cancer. Cancers (Basel), 15, Article No. 233.
https://doi.org/10.3390/cancers15010233 |
| [34] | Yuan, Y., Lee, J.S., Yost, S.E., et al. (2021) A Phase II Clinical Tri-al of Pembrolizumab and Enobosarm in Patients with Androgen Receptor-Positive Metastatic Triple-Negative Breast Cancer. Oncologist, 26, e99-e217.
https://doi.org/10.1002/onco.13583 |
| [35] | Solinas, C., Aiello, M., Migliori, E., et al. (2020) Breast Cancer Vaccines: Heeding the Lessons of the Past to Guide a Path forward. Cancer Treatment Reviews, 84, Article ID: 101947. https://doi.org/10.1016/j.ctrv.2019.101947 |
| [36] | Chung, V., Kos, F.J., Hardwick, N., et al. (2019) Evaluation of Safety and Efficacy of P53MVA Vaccine Combined with Pembrolizumab in Patients with Advanced Solid Cancers. Clinical and Translational Oncology, 21, 363-372.
https://doi.org/10.1007/s12094-018-1932-2 |
| [37] | Song, H.N., Jin, H., Kim, J.H., et al. (2021) Abscopal Effect of Radiotherapy Enhanced with Immune Checkpoint Inhibitors of Triple Negative Breast Cancer in 4T1 Mammary Carci-noma Model. International Journal of Molecular Sciences, 22, Article No. 10476. https://doi.org/10.3390/ijms221910476 |
| [38] | Pointer, K.B., Pitroda, S.P. and Weichselbaum, R.R. (2022) Radio-therapy and Immunotherapy: Open Questions and Future Strategies. Trends in Cancer, 8, 9-20. https://doi.org/10.1016/j.trecan.2021.10.003 |
| [39] | Ho, A.Y., Barker, C.A., Arnold, B.B., et al. (2020) A Phase 2 Clinical Trial？Assessing the？Efficacy and Safety of Pembrolizumab and Radiotherapy in Patients with Metastatic Tri-ple-Negative Breast Cancer. Cancer, 126, 850-860.
https://doi.org/10.1002/cncr.32599 |
| [40] | Gujar, S., Pol, J.G., Kim, Y., et al. (2018) Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies. Trends in Immunology, 39, 209-221. https://doi.org/10.1016/j.it.2017.11.006 |
| [41] | Wang, G., Kang, X., Chen, K.S., et al. (2020) An Engineered Onco-lytic Virus Expressing PD-L1 Inhibitors Activates Tumor Neoantigen-Specific T Cell Responses. Nature Communica-tions, 11, Article No. 1395.
https://doi.org/10.1038/s41467-020-15229-5 |
| [42] | Sun, K., Xu, Y., Zhang, L., et al. (2022) A Phase 2 Trial of En-hancing Immune Checkpoint Blockade by Stereotactic Radiation and in Situ Virus Gene Therapy in Metastatic Tri-ple-Negative Breast Cancer. Clinical Cancer Research, 28, 4392-4401. https://doi.org/10.1158/1078-0432.CCR-22-0622 |
